About Vimentin-type intermediate filament-associated coiled-coil protein
Vimentin-type intermediate filament-associated coiled-coil protein (VMAC) is a protein
from Homo sapiens identified by UniProt accession
Q2NL98, 169 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Vimentin-type intermediate filament-associated coiled-coil protein |
|---|
| UniProt accession | Q2NL98 |
|---|
| Gene | VMAC |
|---|
| Organism | Homo sapiens |
|---|
| Length | 169 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (14)
Diseases linked to this target (Open Targets).
- vital capacity · score 0.24
- mitochondrial complex I deficiency · score 0.18
- forced expiratory volume · score 0.14
- monocyte percentage of leukocytes · score 0.09
- eosinophil count · score 0.07
- eosinophil percentage of leukocytes · score 0.07
- balding measurement · score 0.06
- heart rate response to recovery post exercise · score 0.06
- heart rate variability measurement · score 0.05
- hair shape measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q2NL98-F1 | alphafold | PREDICTED | 85.23 | — |
Amino-acid sequence (169 residues)
MSAPPALQIR EANAHLAAVH RRAAELEARL DAAERTVHAQ AERLALHDQQ LRAALDELGR AKDREIATLQ EQLMTSEATV HSLQATVHQR DELIRQLQPR AELLQDICRR RPPLAGLLDA LAEAERLGPL PASDPGHPPP GGPGPPLDNS TGEEADRDHL QPAVFGTTV
Explore Vimentin-type intermediate filament-associated coiled-coil protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets